Impact of covid-19 on pediatric clinical ...
Document type :
Article dans une revue scientifique: Lettre à l'éditeur
DOI :
PMID :
Permalink :
Title :
Impact of covid-19 on pediatric clinical research in france
Author(s) :
Flamein, Florence [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
Gottrand, fréderic [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Patel, Maya Laxmi [Auteur]
Niche, Nutrition, Cancer et métabolisme oxydatif [N2Cox]
Hankard, Regis [Auteur]
Niche, Nutrition, Cancer et métabolisme oxydatif [N2Cox]
Centre de Recherche Saint-Antoine [UMRS893]
Gottrand, fréderic [Auteur]

Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Patel, Maya Laxmi [Auteur]
Niche, Nutrition, Cancer et métabolisme oxydatif [N2Cox]
Hankard, Regis [Auteur]
Niche, Nutrition, Cancer et métabolisme oxydatif [N2Cox]
Journal title :
CMAJ . Canadian Medical Association journal = journal de l'Association medicale canadienne
Abbreviated title :
Can. Med. Assoc. J.
Volume number :
192
Pages :
E589-E589
Publication date :
2020-05-25
ISSN :
0820-3946
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
As stated by Cheng and colleagues,1 temptations to use unproven medications and strategies instead of relying on scientific evidence are high when facing the frightening coronavirus disease 2019 (COVID-19) pandemic. Most ...
Show more >As stated by Cheng and colleagues,1 temptations to use unproven medications and strategies instead of relying on scientific evidence are high when facing the frightening coronavirus disease 2019 (COVID-19) pandemic. Most medical and scientific communities have reacted promptly to better fight the disease. This is a particular challenge in pediatric clinical research. PEDSTART (www.pedstart.org/en) is the national network of French pediatric clinical research centres. A task force has been created to gather all national research initiatives and anticipate the consequences of COVID-19 on pediatric clinical research. At present, we have identified no fewer than 15 projects at different stages of maturity involving pediatric patients. Overlap between studies is frequent, and multiplicity of trials may jeopardize a relevant approach. Each pediatric clinical investigation centre had to reorganize itself rapidly, while meeting the triple requirement of limiting travel and contact with patients, protecting hospital staff from infection, and reducing the activity of the hospital to ensure there are enough staff and beds for patients with COVID-19. Negative and positive effects have been observed. Although COVID-19 has strengthened team cohesion and involvement, we have to face a decrease in activity of pediatric clinical research. Supply management of investigational medicinal products and good clinical practices will be challenged by unprecedented adaptations of research infrastructure. This period may be a chance to merge projects and to join forces to deal with the resumption of “usual” activity, which will be a challenging task in itself. We encourage and support the merging of risk-mitigation activities at an international level to better anticipate and respond to the impact of COVID-19 on ongoing and future pediatric clinical research.Show less >
Show more >As stated by Cheng and colleagues,1 temptations to use unproven medications and strategies instead of relying on scientific evidence are high when facing the frightening coronavirus disease 2019 (COVID-19) pandemic. Most medical and scientific communities have reacted promptly to better fight the disease. This is a particular challenge in pediatric clinical research. PEDSTART (www.pedstart.org/en) is the national network of French pediatric clinical research centres. A task force has been created to gather all national research initiatives and anticipate the consequences of COVID-19 on pediatric clinical research. At present, we have identified no fewer than 15 projects at different stages of maturity involving pediatric patients. Overlap between studies is frequent, and multiplicity of trials may jeopardize a relevant approach. Each pediatric clinical investigation centre had to reorganize itself rapidly, while meeting the triple requirement of limiting travel and contact with patients, protecting hospital staff from infection, and reducing the activity of the hospital to ensure there are enough staff and beds for patients with COVID-19. Negative and positive effects have been observed. Although COVID-19 has strengthened team cohesion and involvement, we have to face a decrease in activity of pediatric clinical research. Supply management of investigational medicinal products and good clinical practices will be challenged by unprecedented adaptations of research infrastructure. This period may be a chance to merge projects and to join forces to deal with the resumption of “usual” activity, which will be a challenging task in itself. We encourage and support the merging of risk-mitigation activities at an international level to better anticipate and respond to the impact of COVID-19 on ongoing and future pediatric clinical research.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:45:45Z
2024-03-27T10:45:44Z
2024-03-27T10:45:44Z